Latanoprost
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Latanoprost: From Glaucoma to Primary Hereditary Glaucoma
One-Sentence Summary
Latanoprost is a prostaglandin F2α (PGF2α) analogue whose established, worldwide use is in glaucoma and ocular hypertension. The TxGNN model predicts it may also be effective for Primary Hereditary Glaucoma, a rarer genetic subtype, and this is best understood as an extension of its existing use rather than a novel repurposing hypothesis. Currently 1 completed Phase 2 clinical trial and no published literature support this specific indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not on file — no Taiwan licence record exists (market status: Not marketed, 0 ARTG/TFDA entries). Latanoprost’s globally recognised original use is glaucoma / ocular hypertension, per the mechanistic rationale in this evidence pack. |
| Predicted New Indication | Primary Hereditary Glaucoma |
| TxGNN Prediction Score | 99.88% |
| Evidence Level | L2 |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Latanoprost is a PGF2α receptor agonist. It lowers intraocular pressure by increasing uveoscleral (uveal-scleral) outflow of aqueous humour — this is the standard, well-established pharmacological mechanism underlying its use in glaucoma treatment. (Formal DrugBank-curated MOA text was not available in this evidence pack; the mechanism above is drawn from the repurposing rationale supplied alongside the prediction.)
Primary Hereditary Glaucoma is a genetic subtype within the same broad glaucoma disease category that latanoprost already treats. The evidence pack itself flags this explicitly: this is not a novel mechanistic hypothesis, but rather an extension of an already-proven indication into a hereditary/paediatric subgroup. Because the drug’s IOP-lowering mechanism is disease-subtype-agnostic (it acts on aqueous outflow regardless of the underlying genetic cause of raised pressure), extrapolation to hereditary glaucoma is pharmacologically reasonable and is directly supported by a completed paediatric trial (below).
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT01527682 | Phase 2 | Completed | 37 | Evaluated the ocular hypotensive effect and safety of latanoprost vs dorzolamide in patients with primary paediatric glaucoma refractory to surgery. |
No ANZCTR-registered trials were identified for this indication.
Literature Evidence
Currently no related literature available.
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The predicted indication represents a mechanistically well-grounded extension of latanoprost’s known glaucoma-lowering effect into a hereditary subtype, supported by one completed Phase 2 paediatric trial (L2 evidence). However, safety documentation (warnings, contraindications, drug interactions) and formal local regulatory status are currently unavailable, so this cannot yet move to unconditional approval.
To proceed, the following is needed:
- TFDA/TGA-approved Product Information, including warnings and contraindications (currently a Blocking data gap)
- Formal DrugBank-curated mechanism of action record
- Confirmation of drug interaction (DDI) profile — current query returned no results
- Additional trial or registry evidence specific to hereditary glaucoma subtypes beyond the single paediatric study identified
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.